|
Replimune Group Inc (NASDAQ: REPL) |
|
Replimune Group Inc
REPL's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Replimune Group Inc 's sales fell
in the fourth quarter of 2025 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.76 %
Replimune Group Inc net loss increased from $-55 millions, to $-74 millions in fourth quarter of 2025,
• More on REPL's Growth
|
|
Replimune Group Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 20.37 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.17.
• More on REPL's Valuation
|
|
|
|
|
Replimune Group Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 20.37 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.17.
Replimune Group Inc Price to Book Ratio is at 1.8 lower than Industry Avg. of 1869. and higher than S&P 500 Avg. of 0.01
• More on REPL's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com